Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced […]
Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. […]
This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated […]
In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially […]
In this JAMA Surgery Original Investigation, the researchers fielded a Swedish cohort study of 48,986 women to discover whether breast conservation offers a survival benefit compared with mastectomy when results are adjusted for main confounders such as comorbidity and socioeconomic status. The main outcomes and measures were overall survival (OS) and breast cancer–specific survival (BCSS).
Clinical Advances in Hematology & Oncology presents a review of selected presentations from the 2020 SABCS Virtual Symposium, which took place in December 2020. Expert commentary is provided by Joyce A. O’Shaughnessy, MD of Baylor University Medical Center and the Director of the Breast Cancer Research Program, Texas Oncology, US Oncology, in Dallas.
According to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Institute for Cancer Immunotherapy, a microbe found in the colon and commonly associated with the development of colitis and colon cancer may also play a role in the development of some breast cancers.
This review and commentary from the ESMO Virtual Congress 2020 features a look at the following trials: ASCENT (sacituzumab govitecan-hziy), IMpassion130 (atezolizumab + nab-paclitaxel), IMpassion131 (first-line paclitaxel +/– atezolizumab), IPATunity130 (ipatasertib + paclitaxel), SEASTAR (rucaparib + sacituzumab govitecan), FLIPPER (fulvestrant/palbociclib), SOLAR-1 (alpelisib + fulvestrant), and FURVA (vandetanib + fulvestrant).
The American Society of Clinical Oncology (ASCO) published a guideline update about the selection of optimal adjuvant chemotherapy regimens and targeted therapy for early breast cancer, namely trastuzumab emtansine. In a second recommendation, the ASCO guideline addressed the use of biosimilar forms of trastuzumab—five of which have been approved by the FDA.
Another win for Merck and Keytruda, as the FDA granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 based on PFS. The FDA also approved a companion diagnostic, PD-L1 IHC 22C3 pharmDx.